Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells

Blood

Volumn 123, Issue 24, 2014, Pages 3780-3789

  El Mabhouh, Amal A ^a   Ayres, Mary L ^a   Shpall, Elizabeth J ^a   Baladandayuthapani, Veerabhadran ^a   Keating, Michael J ^a   Wierda, William G ^a   Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CASPASE; FLUDARABINE; HISTONE H2AX; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53;

APOPTOSIS; ARTICLE; BONE MARROW; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; COCULTURE; CONTROLLED STUDY; DNA DAMAGE; DNA SYNTHESIS; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LIMIT OF DETECTION; LYMPHOCYTE; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RNA SYNTHESIS; STROMA CELL; UNSCHEDULED DNA SYNTHESIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE MARROW CELLS; CELLS, CULTURED; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NITROGEN MUSTARD COMPOUNDS; PRIMARY CELL CULTURE; STROMAL CELLS; TIME FACTORS; VIDARABINE;

EID: 84902581204     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-541433     Document Type: Article

References (54)

1. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol. 2002;29(4 Suppl 13):4-11. (Pubitemid 34857890)
2. Gandhi V, Burger JA. Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block. Clin Cancer Res. 2009;15(24):7456-7461.
3. Foon KA, Hallek MJ. Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia. 2010;24(3):500-511.
4. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27(26):4378-4384.
5. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009;27(9):1492-1501.
6. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750-1757.
7. Catovsky D, Richards S, Matutes E, et al UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370(9583):230-239. (Pubitemid 47069536)
8. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7):793-798. (Pubitemid 350002879)
9. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088. (Pubitemid 46211313)
10. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-980.
11. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4070-4078. (Pubitemid 46211312)
12. Buschfort C, Muller MR, Seeber S, Rajewsky MF, Thomale J. DNA excision repair profiles of normal and leukemic human lymphocytes: functional analysis at the single-cell level. Cancer Res. 1997;57(4):651-658. (Pubitemid 27085648)
13. Geleziunas R, McQuillan A, Malapetsa A, et al. Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J Natl Cancer Inst. 1991;83(8):557-564.
14. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001;7(11):3580-3589. (Pubitemid 33069998)
15. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem. 1990;265(27):16617-16625.
16. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res. 2005;11(18):6745-6752. (Pubitemid 41339018)
17. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41(2):93-103. (Pubitemid 34264036)
18. Ogura M, Uchida T, Taniwaki M, et al Japanese Bendamustine Lymphoma Study Group. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010;101(9):2054-2058.
19. Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114(20):4441-4450.
20. Caspari T. How to activate p53. Curr Biol. 2000;10(8):R315-R317.
21. Hirao A, Kong YY, Matsuoka S, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 2000;287(5459):1824-1827.
22. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 2000;14(3):289-300. (Pubitemid 30106484)
23. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev. 2001;11(1):71-77. (Pubitemid 32119281)
24. Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci. 2006;31(7):402-410. (Pubitemid 44038916)
25. Leoni LM, Hartley JA. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin Hematol. 2011;48(suppl 1):S12-S23.
26. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14(1):309-317. (Pubitemid 351378007)
27. Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol. 2008;134(2):245-253. (Pubitemid 350234070)
28. Roué G, López-Guerra M, Milpied P, et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res. 2008;14(21):6907-6915.
29. Schwänen C, Hecker T, Hübinger G, et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia. 2002;16(10):2096-2105. (Pubitemid 35203454)
30. Yang LY, Li L, Keating MJ, Plunkett W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol. 1995;47(5):1072-1079.
31. Kamiya K, Huang P, Plunkett W. Inhibition of the 3′ -> 5′ exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA. J Biol Chem. 1996;271(32):19428-19435. (Pubitemid 26274061)
32. Catapano CV, Chandler KB, Fernandes DJ. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate. Cancer Res. 1991;51(7):1829-1835.
33. Catapano CV, Perrino FW, Fernandes DJ. Primer RNA chain termination induced by 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate. A mechanism of DNA synthesis inhibition. J Biol Chem. 1993;268(10):7179-7185. (Pubitemid 23105608)
34. Yang SW, Huang P, Plunkett W, Becker FF, Chan JY. Dual mode of inhibition of purified DNA ligase I from human cells by 9-beta-D-arabinofuranosyl-2- fluoroadenine triphosphate. J Biol Chem. 1992;267(4):2345-2349.
35. Huang P, Sandoval A, Van Den Neste E, Keating MJ, Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia. 2000;14(8):1405-1413. (Pubitemid 30599321)
36. Parker WB, Bapat AR, Shen JX, Townsend AJ, Cheng YC. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol. 1988;34(4):485-491.
37. Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL Jr. In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol. 1982;21(2):474-477. (Pubitemid 12139852)
38. Elledge SJ, Davis RW. DNA damage induction of ribonucleotide reductase. Mol Cell Biol. 1989;9(11):4932-4940. (Pubitemid 19275963)
39. Elledge SJ, Zhou Z, Allen JB, Navas TA. DNA damage and cell cycle regulation of ribonucleotide reductase. Bioessays. 1993;15(5):333-339.
40. Hurta RA, Wright JA. Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent. J Biol Chem. 1992;267(10):7066-7071.
41. Kuo ML, Kinsella TJ. Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells. Cancer Res. 1998;58(10):2245-2252. (Pubitemid 28232915)
42. Lee YD, Wang J, Stubbe J, Elledge SJ. Dif1 is a DNA-damage-regulated facilitator of nuclear import for ribonucleotide reductase. Mol Cell. 2008;32(1):70-80.
43. Sandoval MR. Alternations in the expression of ribonucleotide reductase induced by DNA damage in human chronic lymphocytic leukemia cells. Houston, TX: Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston; 1999:109.
44. Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000;404(6773):42-49. (Pubitemid 30143125)
45. Moufarij MA, Sampath D, Keating MJ, Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood. 2006;108(13):4187-4193. (Pubitemid 44913291)
46. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96(8):2655-2663.
47. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94.
48. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
49. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603- 3612.
50. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591-594.
51. Winkler DG, Faia KL, DiNitto JP, et al. PI3K-d and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013;20(11):1364-1374.
52. Flinn I, Patel M, Kahl BS, et al. Phosphoinositide-3-kinase-δ, γ, in patients with chronic lymphocytic leukemia. Paper presented at the Annual Meeting of the American Society of Hematology. December 8-11, 2013. New Orleans, LA.
53. Koenigsmann M, Knauf W, Herold M, et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma - a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO). Leuk Lymphoma. 2004;45(9):1821-1827. (Pubitemid 39004071)
54. Wierda WG, Balakrishnan K, Ferrajoli A, et al. Fludarabine, bendamustine, and rituximab (FBR) chemoimmunotherapy is a safe and active regimen for relapsed/refractory CLL with in vivo mechanism of action for combination chemotherapy [abstract]. Blood. 2012:120 (21):437.